Identification of the Smallest Structure Capable of Evoking Opsonophagocytic Antibodies against Streptococcus pneumoniae Type 14
- 1 October 2008
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 76 (10) , 4615-4623
- https://doi.org/10.1128/iai.00472-08
Abstract
Synthetic overlapping oligosaccharide fragments of Streptococcus pneumoniae serotype 14 capsular polysaccharide (Pn14PS), {6)-[beta-D-Galp-(1 -> 4)-] beta-D-GlcpNAc-(1 -> 3)-beta-D-Galp-(1 -> 4)-beta-D-Glcp-(1 -> 3}(n), were conjugated to CRM197 protein and injected into mice to determine the smallest immunogenic structure. The resulting antibodies were then tested for Pn14PS specificity and for their capacity to promote the phagocytosis of S. pneumoniae type 14 bacteria. Earlier studies have reported that the oligosaccharide corresponding to one structural repeating unit of Pn14PS, i.e., Gal-Glc-(Gal-) GlcNAc, induces a specific antibody response to Pn14PS. The broader study described here, which evaluated 16 oligosaccharides, showed that the branched trisaccharide element Glc-(Gal-) GlcNAc is essential in inducing Pn14PS-specific antibodies and that the neighboring galactose unit at the nonreducing end contributes clearly to the immunogenicity of the epitope. Only the oligosaccharide conjugates that produce antibodies recognizing Pn14PS were capable of promoting the phagocytosis of S. pneumoniae type 14. In conclusion, the branched tetrasaccharide Gal-Glc-(Gal-) GlcNAc may be a serious candidate for a synthetic oligosaccharide conjugate vaccine against infections caused by S. pneumoniae type 14.Keywords
This publication has 45 references indexed in Scilit:
- Immunology of Experimental Synthetic Carbohydrate—Protein Conjugate Vaccines against Streptococcus pneumoniae SerotypesPublished by American Chemical Society (ACS) ,2008
- Discovery of a New Capsular Serotype (6C) within Serogroup 6 ofStreptococcus pneumoniaeJournal of Clinical Microbiology, 2007
- Avidity of the Immunoglobulin G Response to aNeisseria meningitidisGroup C Polysaccharide Conjugate Vaccine as Measured by Inhibition and Chaotropic Enzyme-Linked Immunosorbent AssaysClinical and Vaccine Immunology, 2007
- Block Synthesis of Streptococcus pneumoniae Type 14 Capsular Polysaccharide Structures*Journal of Carbohydrate Chemistry, 2005
- Immunogenicity in a Mouse Model of a Conjugate Vaccine Made with a Synthetic Single Repeating Unit of Type 14 Pneumococcal Polysaccharide Coupled to CRM197Infection and Immunity, 2002
- Chemoenzymic synthesis of oligosaccharide fragments of the capsular polysaccharide of Streptococcus pneumoniae type 14Journal of the Chemical Society, Perkin Transactions 1, 2002
- Comparison of a Classical Phagocytosis Assay and a Flow Cytometry Assay for Assessment of the Phagocytic Capacity of Sera from Adults Vaccinated with a Pneumococcal Conjugate VaccineClinical and Diagnostic Laboratory Immunology, 2001
- Avidity, Potency, and Cross-Reactivity of Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide Serotype 6BInfection and Immunity, 2001
- Pneumococcal Conjugate Vaccine Primes for Polysaccharide‐Inducible IgG2 Antibody Response in Children with Recurrent Otitis Media AcutaThe Journal of Infectious Diseases, 1999
- Effect of Mucosal and Systemic Immunization with Pneumococcal Polysaccharide Type 3, 4 and 14 in the RatScandinavian Journal of Immunology, 1992